Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
Discontinued
Reference number: GID-TA10527
The Department for Health and Social Care has asked us to carry out a Single Technology Appraisal of Emapalumab for treating primary haemophagocytic lymphohistiocytosis [ID1438].
The appraisal is expected to start in approximately late August 2019 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late October 2019.